Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03456076
What this trial is testing

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 257
Testing effectiveness (Phase 2)Looking for participantsNCT05713006
What this trial is testing

Alectinib Pharmacokinetic in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIIBALK Gene Mutation
Instituto Nacional de Cancerologia de Mexico 45
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Large-scale testing (Phase 3)Study completedNCT02075840
What this trial is testing

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 303
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Looking for participantsNCT07784959
What this trial is testing

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Who this might be right for
ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more
Nuvectis Pharma, Inc. 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT04223596
What this trial is testing

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Who this might be right for
Lung CancerNSCLCNSCLC Stage IIIB+1 more
Fundación GECP 33
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Not applicableNot Yet RecruitingNCT06736561
What this trial is testing

Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Who this might be right for
ALK PositiveEnsartinibNSCLC+1 more
Harbin Medical University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03202940
What this trial is testing

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Massachusetts General Hospital 16
Not applicableUnknownNCT02502240
What this trial is testing

ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP)

Who this might be right for
Lung Cancer
Instituto Nacional de Cancerologia de Mexico 7,000
Early research (Phase 1)Looking for participantsNCT06225427
What this trial is testing

Gilteritinib for the Treatment of ALK NSCLC

Who this might be right for
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
University of Michigan Rogel Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05955391
What this trial is testing

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 164
Testing effectiveness (Phase 2)Study completedNCT04880863
What this trial is testing

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
NeoTX Therapeutics Ltd. 38
Testing effectiveness (Phase 2)Looking for participantsNCT05241028
What this trial is testing

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Hebei Medical University Fourth Hospital 80
Not applicableStudy completedNCT04351334
What this trial is testing

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Who this might be right for
Non-Small-Cell Lung Carcinoma
Pfizer 161
Early research (Phase 1)Study completedNCT01283516
What this trial is testing

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Who this might be right for
Tumors Characterized by Genetic Abnormalities of ALK
Novartis Pharmaceuticals 304
Testing effectiveness (Phase 2)Study completedNCT02336451
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
Novartis Pharmaceuticals 156
Not applicableUnknownNCT01930474
What this trial is testing

Analysis of Plasma Tumor DNA in Lung Cancer Patients

Who this might be right for
Non Small Cell Lung Cancer Patients
Seoul National University Hospital 200
Not applicableStudy completedNCT02679170
What this trial is testing

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 692
Next Page